Skip to content
AnalystLens

Cigna GroupCI

Sector
Healthcare
Industry
Hospital & Medical Service Plans
Exchange
NYSE

Stock Price $CI

Latest filings

You are here#23 of 40 in Healthcare by market cap

Filing record · 2018–202610-K810-Q238-K136

CI filed 8 annual reports (10-K), 23 quarterly reports (10-Q) and 136 current reports (8-K) between 2018 and 2026.

  1. Leadership change8-K · Apr ’20Apr ’20
  2. Material agreement8-K · Apr ’22Apr ’22
  3. Leadership change8-K · Oct ’25Oct ’25

01—Key figures

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  10. $274.90B
YoY changeLargest recent move+215.7%in FY19Latest +11.2%

1 older move runs past ±150% (largest +215.7%); point at, tap or drag across the bars to read one.

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All CI Financial Metrics57 metrics

Income Statement13

Balance Sheet25

Cash Flow15

Per Share4

02—Overview

Cigna Group Financial Overview 2021–2025

Updated Jul 10, 2026

After absorbing a substantial equity write-down in the prior year, The Cigna Group rebounded to deliver a 73% surge in shareholders' net income to $5.96 billiona in FY2025. This dramatic swing underscores a highly deliberate corporate pivot: the company is systematically shedding its traditional medical risk portfolio to double down on its highly profitable pharmacy and specialty care engine.

This transformation is anchored by the Evernorth Health Services segment, where adjusted revenue climbed from $131.9 billionb in FY2021 to a massive $235 billion in FY2025. To fund this expansion and consolidate focus, management aggressively optimized the corporate umbrella. In March 2025, the company finalized the sale of its Medicare Advantage operations to HCSC for $4.9 billion in cash. While this divestiture intentionally shrank total medical customers by 5%, underlying business strength still allowed overall adjusted income from operations to rise 4% to $8.01 billion for the year.

The company simultaneously executed a disciplined capital return strategy, highlighted by $7.0 billionc in stock repurchases during FY2024. By the close of FY2025, the market valued the leaner, services-focused enterprise at a $72.5 billion market cap. Shares ended the year at $275.23, trading at a conservative 12.4x earnings multiple on $22.18 in earnings per share.

Recent Developments (Q4 2025 and Q1 2026)

Cigna entered Q1 2026 with a major leadership transition. Brian C. Evanko will succeed David M. Cordani as Chief Executive Officer on July 1, 2026. First-quarter total revenues grew 5% year-over-year to $68.5 billiond, driving a 25% increase in net income to $1.65 billion. The Evernorth segment led this expansion, posting a 9% jump in adjusted revenues.

Bulls argue the strategic pivot is paying off, as Cigna Healthcare achieved an 18% increase in pre-tax adjusted income, highlighting robust margin expansion. Conversely, bears warn the 21% drop in Cigna Healthcare adjusted revenues during Q1 2026 pressures the enterprise to maintain aggressive Evernorth growth to offset top-line shrinkage. The stock traded at 13.1x earnings as of April 30, 2026.

What to watch: the CEO transition on July 1, 2026; realization of $500 millione in targeted savings from the new rebate-free pharmacy model.

03—Filings

Recent SEC Filings

  1. 8-KCigna Group 8-K Report, Executive Changes (Oct 9, 2026)The Cigna Group (CI) has announced a significant change to its Board of Directors. Donna F. Zarcone has informed the Board of her intention to retire as a director effective December 31, 2026. This development, detailed in an 8-K filing dated October 9, 2026, is presented as a planned retirement and is not attributed to any disputes or disagreements with the company. While the departure itself may not have an immediate operational impact, investors often scrutinize board composition and leadership transitions. Ms. Zarcone's retirement signifies a shift in the Board's experience and perspectives. Investors should monitor the company's subsequent announcements regarding the election of new directors or adjustments to committee memberships to understand the ongoing governance strategy and ensure continued oversight and strategic guidance for The Cigna Group.
  2. 8-KCigna Group 8-K Report, Regulation FD Disclosure (Sep 30, 2026)The Cigna Group (CI) furnished an 8-K on September 30, 2026 tied to its 2026 Investor Day, in which it reaffirmed full-year 2026 guidance rather than changing it. Management expects consolidated adjusted revenues of about $280 billion, adjusted EPS of at least $30.45, Evernorth Health Services adjusted income from operations of at least $6.9 billion, Cigna Healthcare adjusted income from operations of at least $4.55 billion, and a Cigna Healthcare medical care ratio of 83.7% to 84.7%. The reaffirmation signals stability in the current outlook, which was previously set in the July 30, 2026 earnings release. The main new information is strategic and long-term. Management introduced a "Lead to One" vision centered on personalization at scale and complex care leadership, and announced 2026–2030 targets of a 10–14% adjusted EPS CAGR and roughly $50 billion in cumulative operating cash flow. It also unveiled a new $3 billion multi-year modernization and productivity program intended to be self-funding, focused on process streamlining, AI-enabled tools, and supplier/vendor management. Investors will want to assess whether this program delivers net margin improvement without disrupting operations. The filing also reiterates that the outlook excludes the effects of any business combinations after the report date, and includes expected share repurchases and 2026 dividends. Forward-looking statements carry standard risks, including medical cost trends, drug pricing and pharmacy marketplace shifts, government program exposure, regulatory changes, and cyber and AI-related risks. The 10–14% EPS growth target and cash flow goals are multi-year aspirations that depend on execution and external conditions, so they should be weighed with appropriate caution.
  3. 8-KCigna Group 8-K Report, Financial Results (Jul 30, 2026)The Cigna Group (CI) reported second quarter 2026 results on July 30, 2026, with total revenues up 7% year over year to $71.7 billion and shareholders' net income of $1.7 billion, or $6.29 per share, versus $5.71 in Q2 2025. Adjusted income from operations rose 6% to $2.1 billion, or $7.78 per share, versus $7.20 a year earlier. The growth was driven mainly by Cigna Healthcare, where adjusted pre-tax income increased 17% on an improved U.S. Employer margin, while Evernorth Health Services' adjusted pre-tax income fell 2% as Pharmacy Benefit Services declined 27% on client and customer-focused initiatives. Specialty and Care Services grew adjusted pre-tax income 22%. Management raised its full-year 2026 adjusted income from operations outlook to at least $30.45 per share, up $0.10, and increased the Cigna Healthcare pre-tax outlook by $25 million to at least $4.55 billion. The Evernorth pre-tax outlook is at least $6.9 billion, and the Cigna Healthcare medical care ratio is guided to 83.7% to 84.7%. The SG&A expense ratio improved to 4.8% from 5.1%, reflecting operating efficiency. The quarter also showed some top-line pressure. Total customer relationships fell 3% from year-end 2025 to 182.8 million, driven by a 4% decline in pharmacy customers from expected client transitions and lower health plan membership. Medical customers grew 2% to 18.4 million. The company also announced in April 2026 its planned exit from the Individual and Family Plans medical business effective January 1, 2027. Through July 29, 2026, it repurchased 0.9 million shares for about $250 million.
  4. 8-KCigna Group 8-K Report, Regulation FD Disclosure (May 13, 2026)The Cigna Group (CI) has issued an 8-K filing on May 13, 2026, to reaffirm its previously issued full-year 2026 outlook. During upcoming investor meetings, company officials expect to confirm their projected consolidated adjusted income from operations on a per-share basis of at least $30.35. This affirmation signals management's confidence in the company's ongoing performance and its ability to meet financial targets for the year. The filing also provides a definition of consolidated adjusted income from operations, a key non-GAAP metric used by management to assess underlying business performance. While the company is unable to provide a GAAP reconciliation for this forward-looking metric due to the unpredictable nature of certain components like investment gains/losses and special items, investors should note that this measure is distinct from GAAP shareholders' net income. The reaffirmation of guidance is a significant data point for investors as they evaluate The Cigna Group's financial trajectory and operational stability.
  5. 8-KCigna Group 8-K Report, Financial Results (Apr 30, 2026)The Cigna Group (NYSE: CI) reported first quarter 2026 results on April 30, 2026, showing growth in both GAAP and adjusted earnings and raising its full-year 2026 outlook. Shareholders' net income rose to $1.7 billion, or $6.26 per share, from $1.3 billion, or $4.85 per share, a year earlier. Adjusted income from operations increased 12% to $2.1 billion, or $7.79 per share, versus $6.74 in Q1 2025. Total revenues grew 5% to $68.5 billion, driven by Evernorth Health Services, though the divestiture of Medicare businesses to HCSC reduced Cigna Healthcare revenues by 21% year over year. The quality of earnings growth was mixed by segment. Cigna Healthcare was the primary driver, with adjusted pre-tax income up 18% to $1.51 billion and its medical care ratio improving to 79.8% from 82.2%, aided largely by the HCSC transaction. Excluding that divestiture, Cigna Healthcare adjusted revenues rose 8%, supported by premium rate increases. Evernorth Health Services adjusted pre-tax income rose only 2%, with Pharmacy Benefit Services down 28% on expected lower contributions from large clients, partially offset by 20% growth in Specialty and Care Services. Pharmacy customer relationships declined 2% sequentially, while medical customers rose 1%. Management raised its 2026 adjusted EPS outlook to at least $30.35 from $30.25, and raised the Cigna Healthcare pre-tax outlook by $25 million to at least $4.525 billion. The Evernorth pre-tax outlook was reaffirmed at at least $6.9 billion, and the Cigna Healthcare MCR outlook is 83.7% to 84.7%. The debt-to-capitalization ratio improved to 42.3% from 43.0% at year-end 2025, and the SG&A expense ratio fell to 5.4% from 6.4%. Investors should note that the guidance excludes future acquisitions and that a meaningful portion of year-over-year improvement reflects portfolio changes rather than organic growth.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.